These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28007630)

  • 1. Improving the Accuracy of Mesothelioma Diagnosis in China.
    Guo Z; Carbone M; Zhang X; Su D; Sun W; Lou J; Gao Z; Shao D; Chen J; Zhang G; Hu J; Chen K; Wang F; Pass HI; Yu H; Napolitano A; Yang H; Mao W
    J Thorac Oncol; 2017 Apr; 12(4):714-723. PubMed ID: 28007630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
    Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
    Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
    Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
    Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparing the results of pathologic diagnosis of mesothelioma between Chinese and Japanese experts].
    Lou J; Gao Z; Jiang Z; Chen J; Chen R; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2015 Jan; 33(1):33-6. PubMed ID: 25876971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: Analysis of 28 cases in Southeast China.
    Gao Z; Hiroshima K; Wu X; Zhang J; Shao D; Shao H; Yang H; Yusa T; Kiyokawa T; Kobayashi M; Shinohara Y; Røe OD; Zhang X; Morinaga K
    Am J Ind Med; 2015 Oct; 58(10):1040-9. PubMed ID: 26147229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
    Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
    Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
    Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
    Tandon RT; Jimenez-Cortez Y; Taub R; Borczuk AC
    Arch Pathol Lab Med; 2018 Feb; 142(2):236-242. PubMed ID: 29048219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
    Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
    [No Abstract]   [Full Text] [Related]  

  • 12. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
    Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
    Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
    Carbone M; Adusumilli PS; Alexander HR; Baas P; Bardelli F; Bononi A; Bueno R; Felley-Bosco E; Galateau-Salle F; Jablons D; Mansfield AS; Minaai M; de Perrot M; Pesavento P; Rusch V; Severson DT; Taioli E; Tsao A; Woodard G; Yang H; Zauderer MG; Pass HI
    CA Cancer J Clin; 2019 Sep; 69(5):402-429. PubMed ID: 31283845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelioma: current perspectives.
    Taylor RA; Johnson LP
    West J Med; 1981 May; 134(5):379-83. PubMed ID: 7257347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer.
    Ryan PJ; Oates JL; Crocker J; Stableforth DE
    Respir Med; 1997 Jan; 91(1):57-60. PubMed ID: 9091974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research progress on immunohistochemical diagnostic markers for malignant pleural mesothelioma].
    Pu YQ; Zhang YP; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Nov; 41(11):869-875. PubMed ID: 38073220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
    Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
    Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.